We have located links that may give you full text access.
Cell-autonomous hepatocyte-specific GP130 signalling is sufficient to trigger a robust innate immune response in mice.
Journal of Hepatology 2020 September 26
BACKGROUND&AIM: IL-6 cytokine family members contribute to inflammatory and regenerative processes. Engagement of the signalling receptor subunit gp130 is common to almost all members of the family. In the liver, all major cell types respond to IL-6, making it difficult to delineate cell type-specific effects of IL-6 type cytokines. We therefore generated mouse models for liver cell type-specific analysis of IL-6 signalling.
METHODS: We produced mice with a Cre-inducible expression cassette encoding a designed pre-dimerized constitutive active gp130 variant. We bred these mice to different Cre-drivers to induce transgenic gp130 signalling in distinct liver cell types: hepatic stellate cells (HSCs), cholangiocytes (CCs)/liver progenitor cells (LPCs) or hepatocytes. We phenotyped these mice using multi-omics approaches, immunophenotyping and a bacterial infection model.
RESULTS: Hepatocyte-specific gp130 activation led to the up-regulation of innate immune system components, including acute-phase-proteins. Consequently, we observed peripheral mobilisation and recruitment of myeloid cells to the liver. Hepatic myeloid cells, including liver-resident Kupffer cells were instructed to adopt a bactericidal phenotype which ultimately conferred enhanced resistance to bacterial infection in these mice. We demonstrate that persistent hepatocyte-specific gp130 activation resulted in amyloid A amyloidosis in aged mice. In contrast, we did not observe overt effects of HSC or CC/LPC-specific transgenic gp130 signalling.
CONCLUSIONS: Hepatocyte-specific gp130 activation alone is sufficient to trigger a robust innate immune response in the absence of NFκB activation. We therefore conclude that gp130 engagement e.g. by IL-6 trans-signalling represents a safe-guard mechanism in innate immunity.
METHODS: We produced mice with a Cre-inducible expression cassette encoding a designed pre-dimerized constitutive active gp130 variant. We bred these mice to different Cre-drivers to induce transgenic gp130 signalling in distinct liver cell types: hepatic stellate cells (HSCs), cholangiocytes (CCs)/liver progenitor cells (LPCs) or hepatocytes. We phenotyped these mice using multi-omics approaches, immunophenotyping and a bacterial infection model.
RESULTS: Hepatocyte-specific gp130 activation led to the up-regulation of innate immune system components, including acute-phase-proteins. Consequently, we observed peripheral mobilisation and recruitment of myeloid cells to the liver. Hepatic myeloid cells, including liver-resident Kupffer cells were instructed to adopt a bactericidal phenotype which ultimately conferred enhanced resistance to bacterial infection in these mice. We demonstrate that persistent hepatocyte-specific gp130 activation resulted in amyloid A amyloidosis in aged mice. In contrast, we did not observe overt effects of HSC or CC/LPC-specific transgenic gp130 signalling.
CONCLUSIONS: Hepatocyte-specific gp130 activation alone is sufficient to trigger a robust innate immune response in the absence of NFκB activation. We therefore conclude that gp130 engagement e.g. by IL-6 trans-signalling represents a safe-guard mechanism in innate immunity.
Full text links
Related Resources
Trending Papers
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Anti-Arrhythmic Effects of Heart Failure Guideline-Directed Medical Therapy and Their Role in the Prevention of Sudden Cardiac Death: From Beta-Blockers to Sodium-Glucose Cotransporter 2 Inhibitors and Beyond.Journal of Clinical Medicine 2024 Februrary 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app